Inhibrx Biosciences, Inc. (INBX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Inhibrx Biosciences, Inc. reported revenue of $1.30M, up 550.0% from the prior year. The company ran a net loss, with a net margin of -10773.5%. It held $146.48M in total assets against $138.49M in total liabilities.
Key ratios (FY2025)
-10386.5%
Operating margin
-10773.5%
Net margin
-1752.2%
Return on equity
+550.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $1.30M | $200.0K | $1.80M | — |
| Operating Income | -$135.03M | -$331.45M | -$219.22M | — |
| Net Income | -$140.06M | $1.69B | -$241.36M | — |
| EPS (Diluted) | $-9.04 | $112.62 | $-20.48 | — |
| Total Assets | $146.48M | $180.77M | $307.89M | — |
| Total Liabilities | $138.49M | $47.18M | $264.39M | — |
| Shareholders' Equity | $7.99M | $133.58M | $43.50M | $58.06M |
| Cash & Equivalents | $124.22M | $152.60M | $277.92M | — |
| Operating Cash Flow | -$129.79M | -$194.41M | -$193.31M | — |
| Capital Expenditures | $31.0K | $2.60M | $4.59M | — |
| Shares Outstanding | 14.58M | 14.48M | 47.37M | — |